Ruxolitinib cream + Vehicle

Phase 3Withdrawn
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hand Eczema

Conditions

Hand Eczema

Trial Timeline

Jan 31, 2023 โ†’ Sep 22, 2024

About Ruxolitinib cream + Vehicle

Ruxolitinib cream + Vehicle is a phase 3 stage product being developed by Incyte for Hand Eczema. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT05219864. Target conditions include Hand Eczema.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (6)

NCT IDPhaseStatus
NCT05906628Phase 2Completed
NCT05219864Phase 3Withdrawn
NCT05233410Phase 3Withdrawn
NCT05127421Phase 2Completed
NCT04057573Phase 3Completed
NCT04052425Phase 3Completed

Competing Products

17 competing products in Hand Eczema

See all competitors
ProductCompanyStageHype Score
Lebrikizumab + PlaceboEli LillyPhase 3
77
Methylprednisolone TabletJohnson & JohnsonPhase 2/3
65
ABT-981 + Placebo for ABT-981AbbViePhase 2
52
Pimecrolimus Cream 1%NovartisPhase 3
77
tocilizumab + saline solutionRochePhase 3
77
denosumab + PlaceboAmgenPhase 2
51
Dupilumab + PlaceboSanofiPhase 2
51
dupilumab + PlaceboSanofiPhase 3
76
clobetasol propionateGSK plcApproved
84
urea 40% cream + fluocinonide 0.05% cream + tazarotene 0.1% cream + bland emollient cream (Udderly smoothยฎ Udder Cream)BayerPhase 2
49
Ruxolitinib cream + VehicleIncytePhase 2
49
RuxolitinibIncytePhase 1/2
38
Ruxolitinib cream + VehicleIncytePhase 3
74
ARQ-252 cream 0.3% + ARQ-252 cream 0.1% + ARQ-252 Vehicle CreamArcutis BiotherapeuticsPhase 1/2
36
alitretinoinBasilea PharmaceuticaPhase 3
72
alitretinoinBasilea PharmaceuticaPhase 3
72
alitretinoinBasilea PharmaceuticaPhase 3
72